Lancet 376(9742):687697 Hurvitz SA et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Provides gastroprotective effects against damage from NSAIDs and other medications that commonly irritate the digestive tract, supporting safe long-term pharmaceutical use when medically necessary
10.1016/j.ocarto.2022.100256 153 McAlindonT
Discussion BPC 157 has been shown to exert beneficial effects against different pathological conditions [1,2,1026], it induced gastroprotective, analgesic and anti-inflammatory wound healing effects [1,2,1017], also effective against experimental colitis [1016] and showing a particular interaction with the NO-system [14,15,1826]